Diffusion (DFFN) Climbs in Pre-Market Trading for August 5

Equities Staff  |

Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) is active in pre-market trading today, August 5, with shares climbing 11.94% from the last closing price.

The stock is down 54.03% year-to-date and posted 7.85% higher over the last 5 days.

For technical charts, analysis, and more on Diffusion visit the company profile.

Pre-market prices and movements as of 08:04:59 est.

About Diffusion Pharmaceuticals Inc

Diffusion Pharmaceuticals Inc. is an innovative biopharmaceutical company developing novel therapies that enhance the body's ability to deliver oxygen to areas where it is needed most. Diffusion's lead product candidate, TSC, is being developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia, a serious complication of many of medicine's most intractable and difficult-to-treat conditions. In addition to TSC, Diffusion's product candidate DFN-529, a novel, allosteric PI3K/Akt/mTOR Pathway inhibitor, is in early-stage development.

To get more information on Diffusion Pharmaceuticals Inc and to follow the company's latest updates, you can visit the company's profile page here: Diffusion Pharmaceuticals Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Trending Articles

The Strong Dollar Is a Problem for Stocks
3 Ways Finance Teams Can Navigate Inflation Through Automation

Market Movers

Sponsored Financial Content